Pay in 4 interest-free payments of $7.23 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
What stands out: Enforcement focus on mass-marketing, not patient-specific compounding Clear limits on advertising claims, including prohibitions on calling compounded products generic, the same as, or clinically proven Reinforcement of FD&C Act authorities, including misbranding provisions and Section 503A requirements Shift as shortages resolve, removing the legal basis for broad compounding of GLP-1 drugs Expanded compliance tools, including warning letters, seizure, and injunction where violations persist Bottom line: This signals a firmer FDA posture as the GLP-1 market matures, reinforcing long-standing distinctions between FDA-approved drugs and unapproved compounded preparations, particularly when promoted directly to consumers at scale
More frequent monitoring may be needed if symptoms of thyroid dysfunction develop
Semaglutide (Wegovy) was launched in the following year, 2021 and has been directed similarly for the same previous reasons in a short span
Commercial employer-sponsored plans (2026 data): 18% include Wegovy on formulary with prior authorization 11% cover Wegovy only for diabetes-related obesity (off-label coverage of Ozempic is more common) 71% exclude Wegovy entirely from the formulary Medicare Part D plans administered by CVS Caremark: 0% cover Wegovy (federal law prohibits Medicare coverage of weight-loss medications) Some plans cover Ozempic for type 2 diabetes, which patients sometimes use off-label for weight loss Medicaid managed care plans: Coverage varies by state 14 states with CVS Caremark-administered Medicaid plans cover Wegovy as of April 2026 All require prior authorization and BMI 35+ (stricter than commercial plans) The 18% commercial coverage rate represents a decline from 23% in 2024
Each liter of sweat carries with it 5002,000 mg of sodium, plus potassium, magnesium, and calcium
US$ 25.66
US$ 29.39
US$ 28.76
